NIH VideoCast - Development of targeted and immune-based therapies for urothelial carcinomas and rare genitourinary tumors

Skip Navigation

Development of targeted and immune-based therapies for urothelial carcinomas and rare genitourinary tumors

Loading... Loading video...

190 Views

Air date:	Friday, October 7, 2022, 12:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 190 (84 Live, 106 On-demand)
Category:	NIH Director's Seminars
Runtime:	01:00:12
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	NIH Director's Seminar Series Dr. Apolo’s work has focused on the development of targeted therapies, with a focus on angiogenesis, MET inhibitors, and immunotherapies for the treatment of urothelial cancer and rare genitourinary tumors, and to further our understanding of the pathways driving these diseases. She has investigated the patterns of oncogenic tyrosine-kinase pathway-related alterations in bladder cancer for targeted therapy approaches and has demonstrated the innate and adaptive immunomodulatory properties of cabozantinib. From these mechanisms, she has conducted pioneering research into novel therapies for bladder, kidney, and rare genitourinary cancers leading to FDA approval of avelumab for bladder cancer, and cabozantinib/nivolumab combination for kidney cancer. In her talk, she will discuss the clinical development of these therapies, from phase 1 studies through phase 3 clinical trials for the treatment of urothelial cancer and rare genitourinary tumors.

NLM Title:	Development of targeted and immune-based therapies for urothelial carcinomas and rare genitourinary tumors / Andrea Apolo.
Author:	Apolo, Andrea. National Institutes of Health (U.S.),
Publisher:
Abstract:	(CIT): NIH Director"s Seminar Series Dr. Apolo"s work has focused on the development of targeted therapies, with a focus on angiogenesis, MET inhibitors, and immunotherapies for the treatment of urothelial cancer and rare genitourinary tumors, and to further our understanding of the pathways driving these diseases. She has investigated the patterns of oncogenic tyrosine-kinase pathway-related alterations in bladder cancer for targeted therapy approaches and has demonstrated the innate and adaptive immunomodulatory properties of cabozantinib. From these mechanisms, she has conducted pioneering research into novel therapies for bladder, kidney, and rare genitourinary cancers leading to FDA approval of avelumab for bladder cancer, and cabozantinib/nivolumab combination for kidney cancer. In her talk, she will discuss the clinical development of these therapies, from phase 1 studies through phase 3 clinical trials for the treatment of urothelial cancer and rare genitourinary tumors.
Subjects:	Immunotherapy Molecular Targeted Therapy Rare Diseases--therapy Urologic Neoplasms--immunology Urologic Neoplasms--therapy Urothelium--physiopathology
Publication Types:	Lecture Webcast

NLM Classification:	WJ 160
NLM ID:	9918503178906676
CIT Live ID:	46330
Permanent link:	https://videocast.nih.gov/watch=46330